[Results of a multicenter observational program to evaluate the effectiveness of complex therapy of patients with chronic cerebrovascular pathology with cognitive impairment with Cortexin and Neuromexol (CORNELia study)].

Mashin VV, Belova LA, Kotova EY, Dolgova DR, Statenina AP, Belyaeva YK, Dergacheva AS, Israfilova RR

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2023

PMID38147380DOI10.17116/jnevro202312312134PepBankPUB-38147380

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Cortexin (cortical polypeptide complex) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cortexin (cortical polypeptide complex).

01HumanNot a test of Cortexin (cortical polypeptide complex) aloneObservational studyMechanism
In patients with chronic cerebral ischemia, NR2 antibodies decreased from baseline in both the Cortexin plus Neuromexol and comparison groups.
In plain wordsNR2 antibodies decreased in both the Cortexin plus Neuromexol group and the comparison group.
Peptide
Cortexin (cortical polypeptide complex)
Outcome
DecreaseNR2 antibodies
Study
n = 60
Outcome group
Neuroprotection · Nervous system and cognition
Source sentences
Summary
The concentration of antibodies to NR2 decreased compared to the baseline level in both groups (pp<0.05).
3 context sentences(design, population, supporting numbers)
Summary · context
In 30 patients receiving Cortexin and Neuromexol (main group, MG) and 30 patients in the comparison group (CG), biomarkers of ischemic brain damage (NSE, antibodies to NR2, VEGFA) were determined.
Summary · context
To evaluate the effectiveness of complex therapy with Cortexin and Neuromexol in patients with chronic cerebral ischemia (CCI) and cognitive impairment (CI).
Summary · context
The examination was carried out before the start of treatment and after 30 days.
In this study, Cortexin (cortical polypeptide complex) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cortexin (cortical polypeptide complex).
Report a problemFND-3814738004
02HumanNot a test of Cortexin (cortical polypeptide complex) aloneObservational studyMechanism
In patients with chronic cerebral ischemia, NSE levels decreased during Cortexin plus Neuromexol therapy.
In plain wordsIn patients with chronic cerebral ischemia, Cortexin plus Neuromexol therapy was linked to lower NSE levels.
Peptide
Cortexin (cortical polypeptide complex)
Outcome
DecreaseNSE level
Study
n = 30
Outcome group
Neuroprotection · Nervous system and cognition
Measurements
NSE decrease
2 fold
main group during therapy
Source sentences
Summary
During therapy, a 2-fold decrease in the NSE level (p<0.05) was detected in the MG, which indicates a decrease in the structural and functional parameters of biomembrane neurons in the brain.
3 context sentences(design, population, supporting numbers)
Summary · context
In 30 patients receiving Cortexin and Neuromexol (main group, MG) and 30 patients in the comparison group (CG), biomarkers of ischemic brain damage (NSE, antibodies to NR2, VEGFA) were determined.
Summary · context
To evaluate the effectiveness of complex therapy with Cortexin and Neuromexol in patients with chronic cerebral ischemia (CCI) and cognitive impairment (CI).
Summary · context
The examination was carried out before the start of treatment and after 30 days.
In this study, Cortexin (cortical polypeptide complex) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cortexin (cortical polypeptide complex).
Report a problemFND-3814738003
03HumanNot a test of Cortexin (cortical polypeptide complex) aloneObservational studyMechanism
In patients with chronic cerebral ischemia, VEGFA decreased only in the Cortexin plus Neuromexol group.
In plain wordsIn patients with chronic cerebral ischemia, VEGFA decreased only in the Cortexin plus Neuromexol group.
Peptide
Cortexin (cortical polypeptide complex)
Outcome
DecreaseVEGFA level
Study
n = 30
Outcome group
Neuroprotection · Nervous system and cognition
Source sentences
Summary
The concentration of antibodies to NR2 decreased compared to the baseline level in both groups (pp<0.05).
3 context sentences(design, population, supporting numbers)
Summary · context
In 30 patients receiving Cortexin and Neuromexol (main group, MG) and 30 patients in the comparison group (CG), biomarkers of ischemic brain damage (NSE, antibodies to NR2, VEGFA) were determined.
Summary · context
To evaluate the effectiveness of complex therapy with Cortexin and Neuromexol in patients with chronic cerebral ischemia (CCI) and cognitive impairment (CI).
Summary · context
The examination was carried out before the start of treatment and after 30 days.
In this study, Cortexin (cortical polypeptide complex) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cortexin (cortical polypeptide complex).
Report a problemFND-3814738005
04HumanNot a test of Cortexin (cortical polypeptide complex) aloneObservational studyEfficacy outcome
In patients with chronic cerebral ischemia, Cortexin plus Neuromexol therapy was associated with decreased cognitive impairment severity.
In plain wordsIn patients with chronic cerebral ischemia, Cortexin plus Neuromexol therapy was linked to less severe cognitive impairment.
Peptide
Cortexin (cortical polypeptide complex)
Outcome
DecreaseCognitive impairment severity
Study
n: not reported in source
Outcome group
Cognition and memory · Nervous system and cognition
Source sentences
Summary
During therapy with Cortexin and Neuromexol, characteristic signs of a decrease in the severity of CI were noted (p<0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
To evaluate the effectiveness of complex therapy with Cortexin and Neuromexol in patients with chronic cerebral ischemia (CCI) and cognitive impairment (CI).
Summary · context
The examination was carried out before the start of treatment and after 30 days.
In this study, Cortexin (cortical polypeptide complex) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cortexin (cortical polypeptide complex).
Report a problemFND-3814738001
05HumanNot a test of Cortexin (cortical polypeptide complex) aloneObservational studyEfficacy outcome
In patients with chronic cerebral ischemia, Cortexin plus Neuromexol therapy was associated with decreased MGDS depressive symptoms.
In plain wordsIn patients with chronic cerebral ischemia, Cortexin plus Neuromexol therapy was linked to fewer depressive symptoms.
Peptide
Cortexin (cortical polypeptide complex)
Outcome
DecreaseDepressive symptoms
Study
n: not reported in source
Outcome group
Anxiety and mood · Mental health and mood
Source sentences
Summary
A positive effect of therapy on the emotional background of patients was noted, in particular, a decrease in the severity of depressive symptoms on the MGDS scale.
2 context sentences(design, population, supporting numbers)
Summary · context
To evaluate the effectiveness of complex therapy with Cortexin and Neuromexol in patients with chronic cerebral ischemia (CCI) and cognitive impairment (CI).
Summary · context
The examination was carried out before the start of treatment and after 30 days.
In this study, Cortexin (cortical polypeptide complex) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cortexin (cortical polypeptide complex).
Report a problemFND-3814738002

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.